Next earnings date: 5 Nov 2025
Celularity Inc. – NASDAQ:CELU
Founder-led company
Celularity stock price today
$3.54
+1.29
+58.04%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 17 hours
Celularity stock price monthly change
-24.07%
month
Celularity stock price quarterly change
-24.07%
quarter
Celularity stock price yearly change
+1222.31%
year
Celularity key metrics
Market Cap | 51.71M |
Enterprise value | 117.71M |
P/E | 8.16 |
EV/Sales | 4.79 |
EV/EBITDA | -0.81 |
Price/Sales | 3.79 |
Price/Book | 0.56 |
PEG ratio | N/A |
EPS | -10.18 |
Revenue | 14.78M |
EBITDA | -120.27M |
Income | -181.40M |
Revenue Q/Q | -8.44% |
Revenue Y/Y | -20.93% |
Profit margin | -623.67% |
Oper. margin | -236.31% |
Gross margin | 69.35% |
EBIT margin | -236.31% |
EBITDA margin | -813.35% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCelularity stock price history
Celularity stock forecast
Celularity financial statements
| Dec 2022 | 4.12M | 24.43M | 591.77% |
|---|---|---|---|
| Mar 2023 | 3.93M | -64.01M | -1626.86% |
| Jun 2023 | 2.93M | -47.94M | -1632.03% |
| Sep 2023 | 3.78M | -93.87M | -2479.56% |
| 2027 | 285.65M | 22.47M | 7.87% |
|---|
Analysts Price target
Financials & Ratios estimates
| 2024-10-16 | -1.4 | -1.03 |
|---|
| Dec 2022 | 401066000 | 202.16M | 50.41% |
|---|---|---|---|
| Mar 2023 | 362416000 | 206.78M | 57.06% |
| Jun 2023 | 246419000 | 127.91M | 51.91% |
| Sep 2023 | 157192000 | 126.94M | 80.76% |
| Dec 2022 | -29.58M | -779K | 1.68M |
|---|---|---|---|
| Mar 2023 | -14.99M | -3.20M | 12.75M |
| Jun 2023 | -11.02M | -31K | 5.61M |
| Sep 2023 | -8.32M | -228K | 5.73M |
Celularity alternative data
| Aug 2023 | 225 |
|---|---|
| Sep 2023 | 225 |
| Oct 2023 | 225 |
| Nov 2023 | 225 |
| Dec 2023 | 225 |
| Jan 2024 | 225 |
| Feb 2024 | 225 |
| Mar 2024 | 225 |
| Apr 2024 | 225 |
| May 2024 | 225 |
| Jun 2024 | 225 |
| Jul 2024 | 225 |
Celularity other data
18.71%
-4.07%
of CELU is owned by hedge funds
41
-31
28.03M
-6.26M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2023 | 3000000 | 0 |
| Sep 2023 | 0 | 9064539 |
| Oct 2023 | 18715170 | 12614316 |
| Jan 2024 | 43263729 | 0 |
| Insider | Compensation |
|---|---|
Dr. Robert Joseph Hariri M.D., Ph.D. (1959) Founder, Chief Executive Officer & Chairman | $1,840,000 |
Mr. David C. Beers C.F.A., CFA (1970) Chief Financial Officer | $455,940 |
Dr. Peter H. Diamandis M.D., Ph.D. (1961) Co-Founder & Independent Vice Chairman | $32,000 |
-
What's the price of Celularity stock today?
One share of Celularity stock can currently be purchased for approximately $3.54.
-
When is Celularity's next earnings date?
Celularity Inc. is estimated to report earnings on Wednesday, 5 Nov 2025.
-
Does Celularity pay dividends?
No, Celularity does not pay dividends.
-
How much money does Celularity make?
Celularity has a market capitalization of 51.71M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 26.68% to 22.77M US dollars. Celularity made a loss 196.3M US dollars in net income (profit) last year or -$1.03 on an earnings per share basis.
-
What is Celularity's stock symbol?
Celularity Inc. is traded on the NASDAQ under the ticker symbol "CELU".
-
What is Celularity's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Celularity?
Shares of Celularity can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Celularity's key executives?
Celularity's management team includes the following people:
- Dr. Robert Joseph Hariri M.D., Ph.D. Founder, Chief Executive Officer & Chairman(age: 66, pay: $1,840,000)
- Mr. David C. Beers C.F.A., CFA Chief Financial Officer(age: 55, pay: $455,940)
- Dr. Peter H. Diamandis M.D., Ph.D. Co-Founder & Independent Vice Chairman(age: 64, pay: $32,000)
-
Is Celularity founder-led company?
Yes, Celularity is a company led by its founders Dr. Robert Joseph Hariri M.D., Ph.D. and Dr. Peter H. Diamandis M.D., Ph.D..
-
How many employees does Celularity have?
As Jul 2024, Celularity employs 225 workers.
-
When Celularity went public?
Celularity Inc. is publicly traded company for more then 6 years since IPO on 8 Aug 2019.
-
What is Celularity's official website?
The official website for Celularity is celularity.com.
-
Where are Celularity's headquarters?
Celularity is headquartered at 170 Park Avenue, Florham Park, NJ.
-
How can i contact Celularity?
Celularity's mailing address is 170 Park Avenue, Florham Park, NJ and company can be reached via phone at +90 87682170.
Celularity company profile:
Celularity Inc.
celularity.comExchange:
NASDAQ
Full time employees:
120
Industry:
Biotechnology
Sector:
Healthcare
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.
170 Park Avenue
Florham Park, NJ 07932
Florham Park, NJ 07932
CIK: 0001752828
ISIN: US1511902041
CUSIP: 151190105
